Primary Objectives:~• To determine the safety and tolerability, and to establish the recommended dose of the adagrasib and durvalumab combination in advanced NSCLC or GI cancer patients.~Secondary Objectives:~To determine the objective response rate of the adagrasib and durvalumab combination for frontline treatment of advanced NSCLC harboring a KRAS G12C mutation.~To determine the objective response rate of the adagrasib and durvalumab combination for treatment of advanced CRC that have progressed on prior therapy with KRAS G12C inhibitors.~To determine duration of response (DOR) and progression-free survival (PFS) for the combination of the adagrasib and durvalumab in patients with advanced NSCLC harboring a KRAS G12C mutation.~To determine DOR and PFS for the combination of the adagrasib and durvalumab in patients with advanced CRC that have progressed on prior therapy with KRAS G12C inhibitors.~Exploratory Objectives:~To assess predictive biomarkers of response and resistance to the combination of adagrasib and durvalumab.~To assess mechanisms of tumor cell adaptation upon treatment with the combination of adagrasib and durvalumab.~To determine mechanisms of acquired resistance to the combination of adagrasib and durvalumab.~To assess the effect of the combination of adagrasib and durvalumab on the immune tumor microenvironment.~To generate cell lines and patient derived xenograft (PDX) models from tumor samples.~To assess the anti-tumor reactivity of tumor infiltrating lymphocytes (TIL) from tumor biopsies.
To find a recommended dose of the combination of adagrasib and durvalumab that can be given to patients with cancers that have a KRAS G12C mutation.